• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CO8 Design and Rationale of a Global Prospective Observational Study of Real-World Management of Patients with Atrial Fibrillation at High Risk of Stroke- Gardenia
Anticoagulants reduce the risk of stroke in patients with atrial fibrillation (AF). However, due to various causes, including concerns for bleeding, there is treatment variability, including undertreatment or non-treatment, especially in patients with high bleeding risk. The aim of the GARDENIA registry is threefold, 1) to understand the real-world usage of oral anticoagulants (OAC) in patients with AF and elevated risk of bleeding, 2) to evaluate the factors associated with treatment or non-treatment with OACs and adherence to guideline recommended doses of OACs and 3) to determine the incidence of clinical outcomes in th...
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Kakkar, M. Bonaca, R.P. Giugliano, D. Bloomfield, K. Pieper, B.A. Yi, J. Salter, D. Freedholm, S. Parkar, J. Glasspool, G. Kayani, K.A.A. Fox Source Type: research

CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research

CO1 Psychosocial Disorders and Clinical Outcomes Among Older Adults with Atrial Fibrillation: The Sage-AF Study
To examine the association between anxiety, depression, or both, and clinical outcomes, including mortality, stroke, major bleeding, and hospitalizations, among older adults with atrial fibrillation (AF).
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Hamel, J. Mehawej, A. Filippaios, K. John, A. Mishra, H.O. Abu, D. Lessard, M. Tisminetzky, W. Wang, K.V. Tran, T. Paul, J. Saczynski, D. McManus Tags: Clinical Outcomes Source Type: research

PCV44 Real-World Assessment of the Use of Anti-platelet Therapy for Recurrent Stroke Prevention in US Patients without Atrial Fibrillation with Recent Ischemic Stroke or Transient Ischemic Attack
This study evaluated current AP treatment patterns in a real-world setting following an initial ischemic stroke (IS) or transient ischemic attack (TIA).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. O'Brien, D. Milentijevic, R. Roychowdhury, S. Mitra, Y.W. Chen Source Type: research

PCV42 Antiplatelet Treatment Patterns for Secondary Stroke Prevention in the United Kingdom
This study evaluated outpatient antiplatelet treatment patterns for secondary stroke prevention (SSP) after first hospitalization for IS/TIA among UK adults without atrial fibrillation (AF).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Jiang, D. Li, J. Horrow, H. Tamada, A. Kahl, V. Hariharan, A. Avinav, X. Liu, X. Li Tags: Cardiovascular Disorders - Health Service Delivery & Process of Care Source Type: research

Preliminary Results of Restarting Oral Anticoagulant Treatment In Patients with Non-Valvular Atrial Fibrillation Following Intracranial Hemorrhage: A Population-Based Cohort Study
Patients with non-valvular atrial fibrillation (AF) who survive an intracranial hemorrhage (ICH) have an increased risk of ischemic stroke and thromboembolic events (Stroke/SE). An unanswered question is the efficacy and safety of restarting oral anticoagulant treatment (OAC), relative to not restarting in those patients. Our aim was to investigate if restarting OAC among AF patients with an ICH is linked with a lower risk of Stroke/SE and all-cause mortality, but with a small increase in major bleeding compared to not restarting OAC.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: S Perreault, R C ôté, B White-Guay, M Dorais Source Type: research

Long-Term Health Benefits of Treating Non-Valvular Atrial Fibrillation with Apixaban Versus Vitamin K Antagonists In Germany: A Population-Based Modelling Study
Patients with non-valvular atrial fibrillation (NVAF) are five times more likely to suffer a stroke, resulting in enormous personal, social and economic costs. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Nevertheless, VKA therapy requires frequent monitoring, is limited by a narrow therapeutic window and is associated with an increased risk of bleeding. Apixaban, a non-vitamin K oral anticoagulant (NOAC), has shown superior efficacy and reduced risk of major bleeding compared to VKA in the ARISTOTLE trial.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Mueller, S Himmler, E Basic, E Hradetzky Source Type: research

Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research

Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study
This study investigated the effect of co-administration of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the risk of recurrence of such a CV event.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Tran-Duy, FH Vanmolkot, PC Souverein, AW Hoes, A de Boer, CD Stehower, NJ de Wit, MA Joore, F de Vries Source Type: research

Resource Utilisation And Bleeding Events During Anticoagulation Treatment: Real-World Findings From England
This study aimed to estimate the association between healthcare resource use and subsequent bleeding in NVAF patients prescribed VKA in England.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Lister, C Lefevre, I Menown, R Alikhan, L Lacoin, A Bird, M You, E Ridha, D Evans Source Type: research

Treatment Patterns And Quality Of Life Of Patients With Non-Valvular Atrial Fibrillation: An Experience Of A Tertiary Health Care Centers (Treq-Af Study)
This study aimed to determine anti-coagulant treatment patterns and stroke- and bleeding-related risk factors and to evaluate quality of life (QoL) in non-valvular atrial fibrillation (NVAF) patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: B. Ozin, K. Aytemir, O. Arslan, T. Ozcan, M. Kanadasi, M. Demir, M. Gokce, M.M. Sucu, M. Ozdemir, Z. Yigit, M.F. Yavuzkir, A. Oto Source Type: research

Relation Of The Time In Therapeutic Range (Ttr) Of Warfarin To Bleeding Incidences In Patients With Atrial Fibrillation
This study aims to compare and establish relation of time in therapeutic range (TTR) of warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereafter of anticoagulation therapy.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M.A.S. Jasmi, M.N. Mazlan, S. Shaharuddin, H.H. Zulkifly, C.M. Long, R. Hashim, Wahab M.S. Abdul Source Type: research